Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2015 by University of California, San Francisco.
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Genentech, Inc.
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: September 26, 2005
Last updated: April 7, 2015
Last verified: April 2015

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with bevacizumab and to see how well it works in treating patients with advanced neuroendocrine tumors.

Condition Intervention Phase
Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Neoplastic Syndrome
Neuroendocrine Tumor
Biological: bevacizumab
Drug: 5-fluorouracil
Drug: leucovorin
Drug: oxaliplatin
Phase 2
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • The rate of discontinuation due to adverse events (besides neuropathy) possibly related to study treatment. [ Time Frame: During study treatment period, expected to be up to 2 - 18 months; Post-study survival follow-up period, up to 2-8 years ]
    Carcinoid Tumors: 2-8 months median time to progression Pancreatic Neuroendocrine Tumors: 15-18 months median time to progression Poorly Differentiated Neuroendocrine Tumors: 9-11 months median time to progression

  • Objective radiographic response rate [ Time Frame: During study treatment period, expected to be up to 2 - 18 months; Post-study survival follow-up period, up to 2-8 years ]
    Carcinoid Tumors: 2-8 months median time to progression Pancreatic Neuroendocrine Tumors: 15-18 months median time to progression Poorly Differentiated Neuroendocrine Tumors: 9-11 months median time to progression

Secondary Outcome Measures:
  • Overall survival [ Time Frame: until death ]
  • Time to treatment failure [ Time Frame: until patient went off study ]
  • Time to progression [ Time Frame: Until patient went off study and until death ]
  • Biochemical marker response [ Time Frame: Until patient went off study ]

Estimated Enrollment: 70
Study Start Date: June 2005
Estimated Study Completion Date: June 2016
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FOLFOX with Bevacizumab

Starting on Day 1, administered every two weeks:

5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes

Biological: bevacizumab
5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
Other Name: Avastin
Drug: 5-fluorouracil
2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
Other Names:
  • 5-FU
  • Adrucil
Drug: leucovorin
200mg/m2 IV q2 wk on day 1 over a 2-hour period.
Other Name: Folinic acid
Drug: oxaliplatin
200mg/m2 IV q 2 wk on day 1 over a 2-hour period
Other Name: Eloxatin

Detailed Description:



  • Determine the safety of fluorouracil, leucovorin calcium, and oxaliplatin (FOLFOX) with bevacizumab in patients with advanced neuroendocrine tumors.
  • Determine the best overall response rate in patients treated with this regimen.


  • Determine the overall survival of patients treated with this regimen.
  • Determine the time to treatment failure and progression in patients treated with this regimen.
  • Determine the biochemical marker response in patients treated with this regimen.

OUTLINE: This is an open-label, pilot study. Patients are stratified according to tumor type (carcinoid vs islet cell vs poorly differentiated neuroendocrine).

Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 39-102 patients (13-34 per stratum) will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed neuroendocrine tumor (NET)

    • Carcinoid at any site, with or without carcinoid syndrome
    • Pancreatic islet cell tumor

      • Prior streptozocin-based therapy not required
    • Poorly differentiated NET of any primary site (this arm closed to accrual May 2009)

      • Progression with prior treatment with cisplatin-, or carboplatin-based chemotherapy required (unless contraindicated)
  • The following tumors are not allowed:

    • Endocrine organ carcinoma
    • Adrenal gland malignancies
    • Thyroid carcinoma of any histology
    • Pheochromocytoma/paraganglioma
  • Advanced disease

    • Disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent
  • Radiologically or clinically confirmed progressive disease

    • At least 25% increase in radiologically or clinically measurable disease
    • At least 20% increase in the longest diameter (LD) of any previously documented lesion
    • Increase in the sum of the LD of multiple lesions in aggregate of 20%, OR appearance of new lesions OR deterioration in clinical status
  • Measurable disease

    • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional radiographic techniques OR ≥ 10 mm by spiral CT scan

      • Ultrasound or positron-emission tomography alone not sufficient
    • Bone lesions, ascites, peritoneal carcinomatosis, pleural or pericardial effusion, and irradiated lesions are not considered measurable disease
  • Primary tumors of the pancreas should not invade adjacent organs (e.g., stomach or duodenum)
  • No history or evidence of brain or leptomeningeal disease (baseline CNS imaging required if clinical suspicion of CNS metastases)



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • More than 12 weeks


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • No history of hemoptysis or bleeding diathesis
  • No coagulopathy unrelated to therapeutic anticoagulation
  • No significant bleeding events within the past 6 months unless the source of the bleeding has been resected


  • Bilirubin < 2 mg/dL
  • ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases)


  • Creatinine ≤ 2 mg/dL
  • Protein ≤ 1+ OR
  • Protein < 1 gm on 24-hour urine collection
  • Urine protein:creatinine ratio < 1.0


  • History of thromboembolic condition allowed provided patient is on therapeutic anticoagulation at a stable dose for ≥ 4 weeks

    • Concurrent daily prophylactic aspirin (< 325 mg/day) allowed
  • No uncontrolled hypertension, myocardial infarction, clinically significant peripheral arterial ischemia, visceral arterial ischemia or angina within the past 6 months
  • No serious cardiac arrhythmia requiring medication
  • No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past 12 months
  • No history of peripheral vascular disease ≥ grade 2
  • No history New York Heart Association class II-IV congestive heart failure
  • Blood pressure ≤ 160/90 mm Hg


  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No predisposing uncontrolled small bowel or colonic disorder

    • Baseline disease-related diarrhea allowed if symptoms are stable and well-characterized (i.e., # stools/day stable)
  • No gastric or esophageal varices
  • No gastroduodenal ulcers determined to be active by endoscopy


  • No interstitial pneumonia or extensive and symptomatic interstitial fibrosis
  • No lung tumor in close proximity to a major vessel, or with associated cavitation
  • No pleural effusion or ascites that causes ≥ grade 2 dyspnea


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment
  • No significant traumatic injury within the past 28 days
  • No currently active second malignancy other than, non-melanoma skin cancer or carcinoma in situ

    • Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at ≤ 30% risk for relapse
  • No known hypersensitivity reaction attributed to study drugs or to compounds of similar chemical or biological composition
  • No symptomatic peripheral neuropathy > grade 1
  • No other severe disease or comorbidity that would preclude study participation
  • No medically uncontrolled seizures
  • No active infection
  • No serious non-healing wound, ulcer, or bone fracture
  • No psychiatric illness or social situation that would preclude study compliance
  • No other severe, concurrent disease, infection, or co-morbidity that in the judgement of the investigator would constitute a hazard for study participation


Biologic therapy

  • Recovered from prior cytokine therapy
  • At least 4 weeks since prior immunotherapy
  • No prior tyrosine kinase inhibitors or anti-vascular endothelial growth factor (VEGF) angiogenic inhibitors


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • No prior oxaliplatin
  • Prior chemoembolization therapy allowed provided it did not affect areas of measurable disease

Endocrine therapy

  • Prior and concurrent somatostatin analogs allowed for symptomatic control and/or control of hormone hypersecretion only provided treatment was initiated > 3 months prior to study entry


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy and recovered

    • Prior radiotherapy must not affect areas of measurable disease
  • No concurrent radiotherapy to only site of measurable disease


  • Recovered from prior surgery
  • Prior cryotherapy allowed provided it did not affect areas of measurable disease
  • At least 28 days since prior major surgical procedure or open biopsy
  • At least 7 days since minor surgical procedure, fine-needle aspirations, or core biopsy
  • No prior organ allograft
  • No concurrent major surgery


  • At least 4 weeks since prior participation in an experimental drug study
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
  • No halogenated antiviral agents
  • Concurrent antiplatelet agents allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00227617

United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Kaiser Permanente Medical Center - Vallejo
Vallejo, California, United States, 94589
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Genentech, Inc.
Principal Investigator: Emily K. Bergsland, MD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco Identifier: NCT00227617     History of Changes
Other Study ID Numbers: 04458
P30CA082103 ( US NIH Grant/Contract Award Number )
UCSF-04458 ( Other Identifier: Cancer Center )
Study First Received: September 26, 2005
Last Updated: April 7, 2015

Keywords provided by University of California, San Francisco:
WDHA syndrome
recurrent gastrointestinal carcinoid tumor
regional gastrointestinal carcinoid tumor
pulmonary carcinoid tumor
pancreatic polypeptide tumor
recurrent islet cell carcinoma
metastatic gastrointestinal carcinoid tumor

Additional relevant MeSH terms:
Carcinoid Tumor
Neuroendocrine Tumors
Malignant Carcinoid Syndrome
Gastrointestinal Neoplasms
Adenoma, Islet Cell
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Pancreatic Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on April 24, 2017